tiprankstipranks
Revance Therapeutics (RVNC)
NASDAQ:RVNC
Holding RVNC?
Track your performance easily

Revance Therapeutics (RVNC) Financial Statements

624 Followers

Revance Therapeutics Financial Overview

Revance Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.922; its P/E ratio is -2.17; Revance Therapeutics is scheduled to report earnings on March 4, 2025, and the estimated EPS forecast is $-0.19. See an overview of income statement, balance sheet, and cash flow financials.
Sep 24Jun 24Mar 24Dec 23Sep 23
Income Statement-
Total Revenue$ 59.88M$ 65.39M$ 51.94M$ 69.80M$ 56.78M
Gross Profit$ 42.25M$ 47.75M$ 37.02M$ 52.33M$ 37.36M
EBIT$ -30.10M$ -32.22M$ -44.27M-$ -135.78M
EBITDA$ -26.85M$ -28.66M$ -42.89M-$ -133.66M
Net Income Common Stockholders$ -38.12M$ -37.47M$ -53.15M$ -55.76M$ -141.18M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 184.08M$ 232.24M$ 277.07M$ 253.91M$ 300.25M
Total Assets$ 461.56M$ 494.80M$ 508.12M$ 478.45M$ 532.49M
Total Debt$ 483.45M$ 491.64M$ 475.78M$ 478.43M$ 487.90M
Net Debt$ 299.37M$ 259.39M$ 198.71M$ 224.52M$ 187.65M
Total Liabilities$ 624.59M$ 624.54M$ 606.79M$ 630.06M$ 638.69M
Stockholders Equity$ -163.03M$ -160.75M$ -98.67M$ -151.60M$ -106.20M
Cash Flow-
Free Cash Flow$ -41.15M$ -41.60M$ -67.65M-$ -55.47M
Operating Cash Flow$ -41.09M$ -41.13M$ -65.94M$ -42.73M$ -50.96M
Investing Cash Flow$ 23.29M$ -6.89M$ -31.71M$ 2.37M$ 51.59M
Financing Cash Flow$ -6.09M$ -3.41M$ 92.83M$ -1.63M$ 37.46M
Currency in USD

Revance Therapeutics Earnings and Revenue History

Revance Therapeutics Debt to Assets

Revance Therapeutics Cash Flow

Revance Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis